A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50mg oral dose of the γ-secretase inhibitor avagacestat

British Journal of Clinical Pharmacology

Volumn 75, Issue 1, 2013, Pages 136-145

  Tong, Gary ^a   Wang, Jun Sheng ^a   Sverdlov, Oleksandr ^a   Huang, Shu Pang ^a   Slemmon, Randy ^a   Croop, Robert ^a   Castaneda, Lorna ^a   Gu, Huidong ^a   Wong, Oi ^a   Li, Hewei ^a   Berman, Robert M ^a   Smith, Christina ^a   Albright, Charles F ^a   Dockens, Randy ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

secretase inhibitor; A 1 40; Avagacestat; Notch biomarkers; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AVAGACESTAT; HYDROCORTISONE; LIOTHYRONINE; NOTCH RECEPTOR; PLACEBO; THYROTROPIN; THYROXINE;

ADULT; AGE; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HUMAN; INFECTION; KIDNEY DISEASE; LYMPHOCYTE SUBPOPULATION; MALE; MUSCULOSKELETAL DISEASE; PARESTHESIA; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OXADIAZOLES; SULFONAMIDES;

EID: 84871112918     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04339.x     Document Type: Article

References (22)

1. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Available at http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf (last accessed 6 February 2012).
2. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101-18.
3. Kinkingnéhun S, Sarazin M, Lehéricy S, Guichart-Gomez E, Hergueta T, Dubois B. VBM anticipates the rate of progression of Alzheimer disease: a 3-year longitudinal study. Neurology 2008; 70: 2201-11.
4. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774.
5. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
6. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Med 2009; 7: 7.
7. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem 2003; 278: 34427-37.
8. Weerkamp F, Luis TC, Naber BA, Koster EE, Jeannotte L, van Dongen JJ, Staal FJ. Identification of Notch target genes in uncommitted T-cell progenitors: no direct induction of a T-cell specific gene program. Leukemia 2006; 20: 1967-77.
9. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003; 4: 721-32.
10. Meredith J Jr, Albright CF, Dockens RC, Olson RE, Lentz KA, Wang J-S, Denton RR, Pilcher G, Zaczek R, Macor JE, Houston J, Wong O, Gu H, Berman RM, Tong G. BMS-708163, a notch-sparing GSI, decreases central Aβ in rats, dogs, and humans with a therapeutic margin relative to notch toxicity. Presented at the 10th International Conference on Alzheimer's and Parkinson's Diseases. 9-13 March 2011, Barcelona, Spain. 2011.
11. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS. Begacestat (GSI-953): a novel, selective thiophene sulphonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009; 331: 598-608.
12. Tong G, Wang J-S, Sverdlov O, Huang S-P, Slemmon R, Croop R, Castaneda L, Gu H, Wong O, Li H, Berman RM, Smith C, Albright CF, Dockens R. Multicenter, randomized, double-blinded, placebo-controlled single ascending-dose study of the oral gamma-secretase inhibitor BMS-708163 (avagacestat): tolerability profile, pharmacokinetics, and pharmacodynamics. Manuscript in press. Clin Ther 2012; 34: 654-67.
13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-8.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
15. Gu H, Deng Y, Wang J, Aubry AF, Arnold ME. Development and validation of sensitive and selective LC-MS/MS methods for the determination of BMS-708163, a gamma-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 2319-26.
16. Oh ES, Mielke MM, Rosenberg PB, Jain A, Fedarko NS, Lyketsos CG, Mehta PD. Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma. J Alzheimers Dis 2010; 21: 769-73.
17. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4.
18. Gibaldi M, Perrier D. In: Noncompartmental Analysis Based on Statistical Moment Theory, in Pharmacokinetics, 2nd edn. 409-17. New York: Marcel Dekker, 1982.
19. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980; 8: 509-34.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
21. Alexander SPH, Mathie A, Peters JA. Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 2011; 164: (1): S1-S324.
22. Burton CR, Meredith JE, Barten DM, Goldstein ME, Krause CM, Kieras CJ, Sisk L, Iben LG, Polson C, Thompson MW, Lin XA, Corsa J, Fiedler T, Pierdomenico M, Cao Y, Roach AH, Cantone JL, Ford MJ, Drexler DM, Olson RE, Yang MG, Bergstrom CP, McElhone KE, Bronson JJ, Macor JE, Blat Y, Grafstrom RH, Stern AM, Seiffert DA, Zaczek R, Albright CF, Toyn JH. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression. J Biol Chem 2008; 283: 22992-3003.